Literature DB >> 20096295

Toxicity of (22R,23R)-22,23-dihydroxystigmastane derivatives to cultured cancer cells.

Alexander Yu Misharin1, Arif R Mehtiev, Vladimir N Zhabinskii, Vladimir A Khripach, Vladimir P Timofeev, Yaroslav V Tkachev.   

Abstract

Toxicity of eight 22,23-dihydroxystigmastane derivatives (four pairs of (22R,23R)- and (22S,23S)-isomers differing in steroid backbone structure) to human breast carcinoma MCF-7 cells was compared. For every pair of structurally related compounds, (22R,23R) isomer was found to be significantly more toxic than (22S,23S) isomer. Computational analysis showed that side chain of (22R,23R)-22,23-dihydroxystigmastane derivatives is rigid, whereas that of (22S,23S)-isomers is rather flexible. Structure of steroid backbone significantly affects cytotoxicity of (22R,23R)-22,23-dihydroxystigmastane derivatives to human breast carcinoma MCF-7 cells, human ovary carcinoma CaOv cells, and human prostate carcinoma LnCaP cells. (22R,23R)-3beta,22,23-trihydroxystigmast-5-ene and (22R,23R)-3beta,22,23-trihydroxystigmast-5-en-7-one, both comprising equatorial 3beta-hydroxyl group, exhibited the highest cytotoxicity, while the most polar 28-homobrassinolide and 28-homocastasterone, both comprising 2alpha,3alpha-dihydroxy groups, exhibited the lowest toxicity. Binding of (22R,23R)-22,23-dihydroxystigmastane derivatives to plasmatic membrane was suggested to be important for cytotoxicity. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096295     DOI: 10.1016/j.steroids.2010.01.006

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  1 in total

1.  Synthesis of ergostane-type brassinosteroids with modifications in ring A.

Authors:  Vladimir N Zhabinskii; Darya A Osiyuk; Yuri V Ermolovich; Natalia M Chaschina; Tatsiana S Dalidovich; Miroslav Strnad; Vladimir A Khripach
Journal:  Beilstein J Org Chem       Date:  2017-11-02       Impact factor: 2.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.